Hiroki Takai

Hiroki joined GB in 2022 and is responsible for Life Science investments in Europe and Israel.
Hiroki started his career as a researcher, earning his PhD on the regulation of gene expression in the worst type of brain cancers at the University of Tokyo.
After graduation, He moved to Boston and conducted research at Harvard Medical School before joining Eli Lilly and Company.
At Eli Lilly, He led the interpretation of clinical trial results with a multinational and interdisciplinary team and devised strategies for disseminating scientific information through scientific articles and conference presentations.
During his MBA at London Business School, He worked for Lilly New Ventures, Eli Lilly's internal organization, investigating Japan's Life Science investment opportunities.
Hiroki enjoys weight training, photography (urban landscapes, architecture, and nature), driving boats, ocean fishing, and spending time with his family.